ATE209902T1 - Neue liposomkomplexe mit erhöhter systemischer verabreichung - Google Patents
Neue liposomkomplexe mit erhöhter systemischer verabreichungInfo
- Publication number
- ATE209902T1 ATE209902T1 AT97938096T AT97938096T ATE209902T1 AT E209902 T1 ATE209902 T1 AT E209902T1 AT 97938096 T AT97938096 T AT 97938096T AT 97938096 T AT97938096 T AT 97938096T AT E209902 T1 ATE209902 T1 AT E209902T1
- Authority
- AT
- Austria
- Prior art keywords
- liposomes
- expression
- highly efficient
- liposome complexes
- systemic administration
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 7
- 238000007910 systemic administration Methods 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2438696P | 1996-08-19 | 1996-08-19 | |
| PCT/US1997/013599 WO1998007408A1 (en) | 1996-08-19 | 1997-08-01 | Novel liposome complexes for increased systemic delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE209902T1 true ATE209902T1 (de) | 2001-12-15 |
Family
ID=21820321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97938096T ATE209902T1 (de) | 1996-08-19 | 1997-08-01 | Neue liposomkomplexe mit erhöhter systemischer verabreichung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6413544B1 (de) |
| EP (1) | EP0955999B1 (de) |
| JP (1) | JP4203835B2 (de) |
| AT (1) | ATE209902T1 (de) |
| AU (1) | AU730771B2 (de) |
| CA (1) | CA2263705C (de) |
| DE (1) | DE69708919T2 (de) |
| WO (1) | WO1998007408A1 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288266B2 (en) * | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| AUPQ002399A0 (en) * | 1999-04-28 | 1999-05-20 | Australian National University, The | Model membrane systems |
| AU5161800A (en) * | 1999-05-24 | 2000-12-12 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| EP1754488A1 (de) | 1999-05-24 | 2007-02-21 | Introgen Therapeutics, Inc. | Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten |
| TR199901199A2 (xx) * | 1999-05-31 | 2001-09-21 | Kocagöz Tanil | Bakteri transformasyon kiti |
| AUPQ259399A0 (en) | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
| US10293056B1 (en) * | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| US6477426B1 (en) * | 2000-06-20 | 2002-11-05 | Celsion Corporation | System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| US20040082521A1 (en) * | 2002-03-29 | 2004-04-29 | Azaya Therapeutics Inc. | Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| US20060003316A1 (en) * | 2002-07-15 | 2006-01-05 | John Simard | Immunogenic compositions derived from poxviruses and methods of using same |
| US20040048260A1 (en) * | 2002-09-10 | 2004-03-11 | Fu-Hsiung Chang | Transfection of nucleic acid |
| US7179484B2 (en) * | 2002-11-06 | 2007-02-20 | Azaya Therapeutics, Inc. | Protein-stabilized liposomal formulations of pharmaceutical agents |
| US7608449B2 (en) | 2003-05-14 | 2009-10-27 | The Regents Of The University Of California | Methods and compositions related to high-titer pseudotyped retroviruses |
| WO2005082396A2 (en) | 2003-12-01 | 2005-09-09 | Introgen Therapeutics, Inc. | Use of mda-7 to inhibit infection by pathogenic organisms |
| ES2388531T3 (es) | 2004-03-19 | 2012-10-16 | Rodos Biotarget Gmbh | Liposomas derivatizados con hidratos de carbono para la selección como diana de dominios de reconocimiento de hidratos de carbono celulares de lectinas CTL/CTLD y suministro intracelular de compuestos terapéuticamente activos |
| WO2007149062A2 (en) * | 2005-03-14 | 2007-12-27 | Board Of Regents, The University Of Texas System | Bioactive fus1 peptides and nanoprticle-polypeptide complexes |
| WO2006101201A1 (ja) * | 2005-03-24 | 2006-09-28 | National University Corporation Hokkaido University | 目的物質を効率的に核内に送達可能なリポソーム |
| EP1940355B1 (de) | 2005-09-30 | 2012-12-19 | Auburn University | Nanoträger zur gezielten Freisetzung eines Wirkstoffs - enthaltend Ansammlungen von auf ein Ziel ausgerichteten Landschaftsphagenproteinen |
| EP1994043A4 (de) | 2006-02-10 | 2009-05-20 | Univ Cincinnati | Phosphatasehemmer-protein 1 als regulator der herzfunktion |
| CN101460055A (zh) | 2006-04-07 | 2009-06-17 | 得克萨斯大学体系董事会 | 和腺伴随病毒-噬菌体颗粒相关的方法和组合物 |
| US8753878B2 (en) | 2006-12-22 | 2014-06-17 | Ewos S.A. | Process and formulation for immunizing fish in aquaculture systems |
| US9273300B2 (en) | 2007-02-07 | 2016-03-01 | Strike Bio, Inc | Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy |
| WO2009049089A1 (en) * | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
| CN101868180A (zh) | 2007-10-09 | 2010-10-20 | 圣路易斯华盛顿州立大学 | 成像粒子 |
| CN106841616B (zh) | 2008-01-25 | 2019-06-04 | 茂体外尔公司 | P53生物标记物 |
| US8563690B2 (en) * | 2008-11-03 | 2013-10-22 | The Board Of Trustees Of The University Of Illinois | Modulation of platelet aggregation |
| US9409983B2 (en) | 2009-07-23 | 2016-08-09 | The Board Of Trustess Of The University Of Illinois | Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases |
| AU2010339809B2 (en) | 2009-12-17 | 2016-05-05 | The Washington University | Antithrombotic nanoparticle |
| US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
| AU2011239414A1 (en) | 2010-04-15 | 2012-11-08 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
| JP6121904B2 (ja) | 2010-09-08 | 2017-04-26 | ハロザイム インコーポレイテッド | 条件的活性治療用タンパク質を評価および同定する、または発展させる方法 |
| JP2014510045A (ja) | 2011-02-08 | 2014-04-24 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
| EP2741784B1 (de) | 2011-03-02 | 2017-05-17 | Board Of Regents, The University Of Texas System | Tusc2 therapien |
| WO2013036799A2 (en) | 2011-09-09 | 2013-03-14 | Fred Hutchinson Cancer Research Center | Methods and compositions involving nkg2d inhibitors and cancer |
| CN104379602B (zh) | 2012-03-08 | 2017-05-03 | 哈洛齐梅公司 | 具有条件活性的抗表皮生长因子受体抗体及其使用方法 |
| CN103565745A (zh) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
| JP2017510542A (ja) | 2014-01-31 | 2017-04-13 | ファクター バイオサイエンス インコーポレイテッド | 核酸生成及び送達のための方法及び製品 |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| JP6925272B2 (ja) * | 2015-01-28 | 2021-08-25 | リアルイン ライフ サイエンス リミテッド | ＰＰＡＲγ発現および核転座を促進する化合物およびそれの治療的使用 |
| EP3543339A1 (de) | 2015-02-13 | 2019-09-25 | Factor Bioscience Inc. | Nukleinsäureprodukte und verabreichungsverfahren dafür |
| JP7014721B2 (ja) | 2015-09-18 | 2022-02-01 | ディーエヌエーアールエックス | インビボでの核酸発現のためのシステム及び方法 |
| LT3370733T (lt) | 2015-11-02 | 2021-10-25 | Board Of Regents, The University Of Texas System | Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai |
| KR20180104597A (ko) | 2015-11-07 | 2018-09-21 | 멀티비르 인코포레이티드 | 암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물 |
| US11845959B2 (en) | 2016-06-16 | 2023-12-19 | The Regents Of The University Of California | Identification of factor that promotes human HSC self-renewal |
| AU2017290805B2 (en) | 2016-07-01 | 2023-11-16 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
| CA3033788A1 (en) | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| WO2018071668A1 (en) | 2016-10-12 | 2018-04-19 | Board Of Regents, The University Of Texas System | Methods and compositions for tusc2 immunotherapy |
| JP2020510624A (ja) | 2016-12-12 | 2020-04-09 | マルチビア インコーポレイテッド | がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物 |
| JP2020511521A (ja) * | 2017-03-23 | 2020-04-16 | ディーエヌエーアールエックス | ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法 |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| US12454561B2 (en) | 2018-03-19 | 2025-10-28 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| WO2019209956A1 (en) | 2018-04-25 | 2019-10-31 | University Of Massachusetts | Artificial exosome composition and related methods |
| WO2019217593A1 (en) * | 2018-05-08 | 2019-11-14 | University Of Florida Research Foundation, Incorporated | Magnetic liposomes and related treatment and imaging methods |
| CN108653750B (zh) * | 2018-06-01 | 2022-04-22 | 成都诺恩基因科技有限公司 | 包裹质粒dna的阳离子脂质体复合物 |
| EP3874273B1 (de) | 2018-10-31 | 2024-03-27 | Arizona Board of Regents on behalf of the University of Arizona | Biomarker und verfahren zur verwendung bei strahlungsinduzierter lungenverletzung |
| US12098212B2 (en) | 2019-08-12 | 2024-09-24 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
| TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| EP4413038A1 (de) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Pd-l1-bindende affimere |
| EP4412711A1 (de) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Serumhalbwertszeiterweiterte pd-l1-bindende polypeptide |
| EP4477665A4 (de) | 2022-02-10 | 2025-08-20 | Affyxell Therapeutics Co Ltd | Stefin-a-proteinvarianten mit spezifischer bindung an cd40l und verwendungen davon |
| EP4514389A1 (de) | 2022-04-29 | 2025-03-05 | Purinomia Biotech, Inc. | Verfahren und zusammensetzungen zur behandlung von eosinophil-bedingten erkrankungen und störungen |
| WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5206027A (en) * | 1990-09-13 | 1993-04-27 | Fuji Photo Film Co., Ltd. | Amphipathic compound and liposome comprising the same |
| CA2134773A1 (en) * | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
-
1997
- 1997-08-01 US US09/242,190 patent/US6413544B1/en not_active Expired - Lifetime
- 1997-08-01 EP EP97938096A patent/EP0955999B1/de not_active Expired - Lifetime
- 1997-08-01 WO PCT/US1997/013599 patent/WO1998007408A1/en not_active Ceased
- 1997-08-01 CA CA002263705A patent/CA2263705C/en not_active Expired - Lifetime
- 1997-08-01 DE DE69708919T patent/DE69708919T2/de not_active Expired - Lifetime
- 1997-08-01 AU AU40502/97A patent/AU730771B2/en not_active Expired
- 1997-08-01 AT AT97938096T patent/ATE209902T1/de not_active IP Right Cessation
- 1997-08-01 JP JP51076598A patent/JP4203835B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4203835B2 (ja) | 2009-01-07 |
| DE69708919T2 (de) | 2002-06-27 |
| CA2263705A1 (en) | 1998-02-26 |
| US6413544B1 (en) | 2002-07-02 |
| US20020028219A1 (en) | 2002-03-07 |
| AU4050297A (en) | 1998-03-06 |
| EP0955999A1 (de) | 1999-11-17 |
| JP2000516630A (ja) | 2000-12-12 |
| AU730771B2 (en) | 2001-03-15 |
| EP0955999B1 (de) | 2001-12-05 |
| DE69708919D1 (de) | 2002-01-17 |
| CA2263705C (en) | 2007-12-04 |
| WO1998007408A1 (en) | 1998-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69708919D1 (de) | Neue liposomkomplexe mit erhöhter systemischer verabreichung | |
| Trubetskoy et al. | Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly (L-lysine)-antibody conjugate in mouse lung endothelial cells | |
| Kawakami et al. | Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes | |
| WO1998019709A3 (en) | Cationic reagents for transfection | |
| ATE237312T1 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
| EP0759694A4 (de) | Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen | |
| ATE362991T1 (de) | Kondensierte plasmid-liposome komplex zur transfektion | |
| Loughrey et al. | A non-covalent method of attaching antibodies to liposomes | |
| EP0964690A4 (de) | Peptid-lipid konjugate, liposome und liposomaler arzneimittelverabreichung | |
| DE69505677D1 (de) | Liposomales verabreichungssystem für biologisch aktive stoffe | |
| PT883602E (pt) | Compostos lipidicos e sua utilizacao por exemplo em lipossomas | |
| DE69730218D1 (de) | Fusogene liposomen | |
| FI963103A0 (fi) | Ei-virusvektori | |
| WO1997011682A3 (en) | Emulsion and micellar formulations for the delivery of biologically active substances to cells | |
| ATE322255T1 (de) | Polyamid-oligomere | |
| CA2219119A1 (en) | Nucleic acid ligand complexes | |
| DE69841536D1 (de) | Zielgerichtete Liposomen zur Verabreichung von Genen | |
| EP0769968A4 (de) | Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden | |
| ATE419833T1 (de) | Modulares zielgerichtetes liposomales verabreichungssytem | |
| EE200000102A (et) | Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene | |
| Chiou et al. | In vivo gene therapy via receptor-mediated DNA delivery | |
| WO1999065461A3 (en) | Cationic amphiphile micellar complexes | |
| ATE359764T1 (de) | Durch liposome vermittelte dna verabreichung | |
| CO5280052A1 (es) | Virosomas cationicos dosper | |
| MX9708111A (es) | Lipidos cationicos para terapia genica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |